Two-year study of cervical cord volume and myelin water in primary progressive multiple sclerosis

Abstract

Background: Spinal cord involvement in multiple sclerosis (MS) is common and an important element in disability. Previous studies demonstrated smaller cervical cord area at the C2 level in MS compared to controls, and a decrease in cord area over 12 months, most marked in primary progressive MS (PPMS). A subset of subjects participating in a multicentre, double-blind, placebo-controlled clinical trial evaluating the efficacy of glatiramer acetate in PPMS (PROMiSe trial) were followed for 2 years.

Methods: 24 PPMS subjects, randomized to placebo (n = 9) and glatiramer acetate (n = 15), and 24 matched controls were studied. Cervical cord volume (CCV) at C2—3 was determined using a 3D inversion recovery (IR)-prepared spoiled-gradient echo sequence. Myelin water fraction (MWF) at C2—3 was obtained using a 32-echo IR-prepared relaxation sequence. Scans were repeated at baseline, years 1 and 2.

Results: Baseline CCV was significantly smaller for PPMS than controls [median (interquartile range) 951 (829—1043) vs. 1072 (1040—1129) mm³, p = 0.0004] and MWF trended to be lower in PPMS cord [median (interquartile range) 0.225 (0.187—0.267) vs. 0.253 (0.235—0.266), p = 0.12]. Baseline CCV correlated with baseline Expanded Disability Status Scale, disease duration, brain white and grey matter volume. In PPMS, CCV was significantly decreased at year 1 (—0.83%, p = 0.04) and year 2 (—1.65%, p = 0.02). Baseline MWF correlated with baseline CCV and brain white and grey matter volume. MWF was significantly decreased from baseline for PPMS at year 2 (—10.5%, p = 0.01). Treatment effect was not detected on change in CCV nor MWF.

Conclusions: Metrics at the level of the cord, including volume and MWF at C2—3, were lower in PPMS than controls and changed over 2 years only in PPMS.

Keywords

atrophy demyelination MRI multiple sclerosis spinal cord

Get full access to this article

View all access options for this article.

References

Nijeholt GJ , van Walderveen MA , Castelijns JA , et al. Brain and spinal cord abnormalities in multiple sclerosis. Correlation between MRI parameters, clinical subtypes and symptoms. Brain 1998; 121: 687-697.

Kidd D. , Thorpe JW , Thompson AJ , et al. Spinal cord MRI using multi-array coils and fast spin echo. II. Findings in multiple sclerosis. Neurology 1993; 43: 2632-2637.

Filippi M. , Campi A. , Colombo B. , et al. A spinal cord MRI study of benign and secondary progressive multiple sclerosis. J Neurol 1996; 243: 502-505.

Liu C. , Edwards S. , Gong Q. , Roberts N. , Blumhardt LD Three dimensional MRI estimates of brain and spinal cord atrophy in multiple sclerosis. J Neurol Neurosurg Psychiatry 1999 ; 66: 323-330.

Losseff NA , Webb SL , O’Riordan JI , et al. Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. Brain 1996; 119: 701-708.

Bieniek M. , Altmann DR , Davies GR , et al. Cord atrophy separates early primary progressive and relapsing remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2006; 77: 1036-1039.

Agosta F. , Absinta M. , Sormani MP , et al. In vivo assessment of cervical cord damage in MS patients: a longitudinal diffusion tensor MRI study. Brain 2007; 130: 2211-2219.

Stevenson VL , Leary SM , Losseff NA , et al. Spinal cord atrophy and disability in MS: a longitudinal study. Neurology 1998 ; 51: 234-238.

Lin X. , Tench CR , Turner B. , Blumhardt LD , Constantinescu CS Spinal cord atrophy and disability in multiple sclerosis over four years: application of a reproducible automated technique in monitoring disease progression in a cohort of the interferon beta-1a (Rebif) treatment trial . J Neurol Neurosurg Psychiatry 2003; 74: 1090-1094.

10.

Webb S. , Munro CA , Midha R. , Stanisz GJ

Is multicomponent T2 a good measure of myelin content in peripheral nerve?

Mag Reson Med 2003; 49: 638-645.

11.

Laule C. , Leung E. , Lis DK , et al. Myelin water imaging in multiple sclerosis: quantitative correlations with histopathology. Mult Scler 2006; 12: 747-753.

12.

Laule C. , Kozlowski P. , Leung E. , et al. Myelin water imaging of multiple sclerosis at 7 T: Correlations with histopathology. Neuroimage 2008; 40: 1575-1580.

13.

MacKay A. , Whittall K. , Adler J. , et al. In vivo visualization of myelin water in brain by magnetic resonance. Mag Reson Med 1994; 31: 673-676.

14.

Whittall KP , MacKay AL , Graeb DA , et al. In vivo measurement of T2 distributions and water contents in normal human brain. Mag Reson Med 1997; 37: 34-43.

15.

Laule C. , Vavasour IM , Moore GRW , et al. Water content and myelin water fraction in multiple sclerosis: A T2 relaxation study. J Neurol 2004; 251: 284-293.

16.

Minty EP , Bjarnason TA , Laule C. , Mackay AL Myelin water measurement in the spinal cord. Magn Reson Med 2009; 61: 883-892.

17.

Wu Y. , Alexander AL , Fleming JO , Duncan ID , Field AS Myelin water fraction in human cervical spinal cord in vivo. J Comput Assist Tomogr 2006; 30: 304-306.

18.

MacMillan EL , Maedler B. , Kolind SH , Yip E. , MacKay AL 3D myelin water imaging in the human spinal cord at 3.0T. In: Proceedings of the International Society of Magnetic Resonance in Medicine. Berlin: Germany, 2007.

19.

MacMillan EL , Curt A. , Maedler B. , Li DKB , Dvorak MF , MacKay AL 3D myelin water imaging of cervical spondylotic myelopathy at 3T. In: Proceedings of the ISMRM. Toronto: Canada, 2008.

20.

Wolinsky JS , Narayana PA , O’Connor P. , et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 2007; 61: 14-24.

21.

Bedell BJ , Narayana PA , Wolinsky JS A dual approach for minimizing false lesion classifications on magnetic resonance images. Magn Reson Med 1997; 37: 94-102.

22.

Wolinsky J. , Narayana P. , He R. Overview of treatment trials: early baseline clinical and MRI data of the PROMiSe trial. In: Filippi M , Comi G (eds), Primary progressive multiple sclerosis. Milan: Springer-Verlag , 2002, pp. 47-62.

23.

Whittall KP , MacKay AL Quantitative interpretation of NMR relaxation data. J Mag Reson 1989; 84: 134-152.

24.

Beaulieu C. , Fenrich FR , Allen PS Multicomponent water proton transverse relaxation and T2-discriminated water diffusion in myelinated and nonmyelinated nerve . Magn Reson Imaging 1998; 16: 1201-1210.

25.

Fenrich FR , Beaulieu C. , Allen PS Relaxation times and microstructures. NMR Biomed 2001; 14: 133-139.

26.

Gareau PJ , Rutt BK , Karlik SJ , Mitchell JR Magnetization transfer and multicomponent T2 relaxation measurements with histopathologic correlation in an experimental model of MS. J Mag Reson Imaging 2000; 11: 586-595.

27.

Graham SJ , Stanchev PL , Bronskill MJ Criteria for analysis of multicomponent tissue T2 relaxation data . Mag Reson Med 1996; 35: 370-378.

28.

Gilmore CP , DeLuca GC , Bo L. , et al. Spinal cord atrophy in multiple sclerosis caused by white matter volume loss. Arch Neurol 2005; 62: 1859-1862.

29.

Filippi M. , Colombo B. , Rovaris M. , et al. A longitudinal magnetic resonance imaging study of the cervical cord in multiple sclerosis. J Neuroimaging 1997; 7: 78-80.